These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29241200)

  • 1. Atypical Hemolytic Uremic Syndrome Associated with Complement Factor H Mutation and IgA Nephropathy: A Case Report Successfully Treated with Eculizumab.
    Nakamura H; Anayama M; Makino M; Makino Y; Tamura K; Nagasawa M
    Nephron; 2018; 138(4):324-327. PubMed ID: 29241200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.
    Sevinc M; Basturk T; Sahutoglu T; Sakaci T; Koc Y; Ahbap E; Akgol C; Kara E; Brocklebank V; Goodship TH; Kavanagh D; Unsal A
    J Med Case Rep; 2015 Apr; 9():92. PubMed ID: 25925370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
    Vondrák K; Seeman T
    Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
    Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Atypical hemolytic uremic syndrome with C3 p.I1157T missense mutation successfully treated with eculizumab].
    Okano M; Matsumoto T; Nakamori Y; Ino K; Miyazaki K; Fujieda A; Sugimoto Y; Tawara I; Yamaguchi M; Ohishi K; Miwa H; Masuya M; Wada H; Katayama N
    Rinsho Ketsueki; 2018; 59(2):178-181. PubMed ID: 29515070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-C5 monoclonal antibody treatment showing pathological resolution of complement-mediated atypical hemolytic uremic syndrome: a case report.
    Kurihara S; Yamaguchi A; Sonoda K; Yamada Y; Harada M; Hashimoto K; Shimojo H; Ikeda Y; Kamijo Y
    BMC Nephrol; 2024 Jul; 25(1):224. PubMed ID: 39009967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report.
    Kim MJ; Lee H; Kim YH; Jin SY; Kim HJ; Oh D; Jeon JS
    BMC Nephrol; 2021 Mar; 22(1):86. PubMed ID: 33691638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
    Fakhouri F; Fila M; Provôt F; Delmas Y; Barbet C; Châtelet V; Rafat C; Cailliez M; Hogan J; Servais A; Karras A; Makdassi R; Louillet F; Coindre JP; Rondeau E; Loirat C; Frémeaux-Bacchi V
    Clin J Am Soc Nephrol; 2017 Jan; 12(1):50-59. PubMed ID: 27799617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemolytic uremic syndrome with multiple organ involvement secondary to complement factor H p.Arg1215X mutation.
    Yeşilbaş O; Şevketoğlu E; Petmezci MT; Kıhtır HS; Benzer M; Berdeli A
    Turk J Pediatr; 2017; 59(5):576-580. PubMed ID: 29745120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postpartum atypical hemolytic uremic syndrome with complement factor H mutation complicated by reversible cerebrovascular constriction syndrome successfully treated with eculizumab.
    Yamaguchi M; Hori M; Hiroshi N; Maruyama S
    Thromb Res; 2017 Mar; 151():79-81. PubMed ID: 28167400
    [No Abstract]   [Full Text] [Related]  

  • 13. Atypical hemolytic-uremic syndrome.
    Kaartinen K; Martola L; Meri S
    Duodecim; 2017; 133(6):539-47. PubMed ID: 29243465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
    Cugno M; Gualtierotti R; Possenti I; Testa S; Tel F; Griffini S; Grovetti E; Tedeschi S; Salardi S; Cresseri D; Messa P; Ardissino G
    J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose-6-Phosphate Dehydrogenase Deficiency Mimicking Atypical Hemolytic Uremic Syndrome.
    Walsh PR; Johnson S; Brocklebank V; Salvatore J; Christian M; Kavanagh D
    Am J Kidney Dis; 2018 Feb; 71(2):287-290. PubMed ID: 29248304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
    Gediz F; Payzin BK; Ecemis S; Güler N; Yilmaz AF; Topcugil F; Berdeli A
    Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab.
    Green H; Harari E; Davidovits M; Blickstein D; Grossman A; Gafter U; Gafter-Gvili A
    Ren Fail; 2014 Aug; 36(7):1119-21. PubMed ID: 24828571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab.
    Sharma S; Pradhan M; Meyers KE; Le Palma K; Laskin BL
    Clin Nephrol; 2015 Sep; 84(3):181-5. PubMed ID: 25816809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
    Alobaidi S; AlDabbagh A; Alamoudi A; Almowarey M; Akl A
    CEN Case Rep; 2019 May; 8(2):139-143. PubMed ID: 30715674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy.
    Hisano M; Ashida A; Nakano E; Suehiro M; Yoshida Y; Matsumoto M; Miyata T; Fujimura Y; Hattori M
    Pediatr Int; 2015 Apr; 57(2):313-7. PubMed ID: 25868950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.